8-K

BRISTOL MYERS SQUIBB CO (BMY)

8-K 2024-02-15 For: 2024-02-13
View Original
Added on April 02, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 8-K


CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 13, 2024


BRISTOL-MYERS SQUIBB COMPANY

(Exact name of registrant as specified in its charter)


Delaware 001-01136 22-0790350
(State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S Employer Identification No.)

Route 206 & Province Line Road,

Princeton, New Jersey 08543

(Address of principal executive offices) (zip code)

Registrant’s telephone number, including area code: (609) 252-4621


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
--- ---
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR<br> 240.14d-2(b))
--- ---
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR<br> 240.13e-4(c))
--- ---

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.10 Par Value BMY New York Stock Exchange
1.000% Notes due 2025 BMY25 New York Stock Exchange
1.750% Notes due 2035 BMY35 New York Stock Exchange
Celgene Contingent Value Rights CELG RT New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Effective February 15, 2024, Mr. Phil Holzer will be appointed Senior Vice President and Controller of Bristol-Myers Squibb Company (the “Company”). Ms. Sharon Greenlees, Senior Vice President and Controller, will assume another role at the Company, effective February 15, 2024.  Mr. Holzer, 48, joined the Company in 2001. Most recently, from 2021 to 2024, he served as Senior Vice President, Finance, Treasury and Tax Operations. Prior to that, he served in multiple roles of increasing responsibility, including Senior Vice President, Enterprise Integrations from 2019 to 2021, Vice President and Head of Finance, Research & Development from 2018 to 2019, Chief Audit Officer from 2015 to 2018, and Vice President, U.S. Commercialization Finance from 2013 to 2015.  Mr. Holzer has a Bachelor of Science degree in Accounting from The University of Tampa and is a Certified Public Accountant.

Mr. Holzer is not a party to any arrangement or understanding regarding his selection as an officer. There are no family relationships between Mr. Holzer and any director or executive officer of the Company. Mr. Holzer is not a party to any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are furnished as part of this Current Report on Form 8-K:

Exhibit<br><br> <br>No. Description
104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

EXHIBIT INDEX

Exhibit<br><br> <br>No. Description
104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BRISTOL-MYERS SQUIBB COMPANY
Dated: February 15, 2024 By: /s/ Kimberly M. Jablonski
Name: Kimberly M. Jablonski
Title: Corporate Secretary